COVID-19相关凝血病与抗血栓药物:一年后的经验总结
本文综述COVID-19相关凝血病的病理生理机制,并回顾过去一年随机对照试验数据,提供抗血栓治疗的高质量证据。门诊及出院后患者不常规推荐药物性血栓预防;非危重住院患者治疗剂量低分子肝素可能改善临床结局;危重患者治疗剂量不改善结局,推荐预防剂量抗凝。
要点
- 门诊及出院后COVID-19患者不常规推荐药物性血栓预防。
- 非危重住院患者治疗剂量低分子肝素可能改善临床结局。
- 危重患者治疗剂量抗凝不改善结局,推荐预防剂量血栓预防。
核心结论
- 门诊及出院后患者不常规推荐药物性血栓预防。
- 非危重住院患者治疗剂量低分子肝素可能改善临床结局。
- 危重患者治疗剂量抗凝不改善结局,推荐预防剂量抗凝血栓预防。
研究设计与样本
- 本文为观点文章,总结COVID-19凝血病病理生理并回顾过去一年随机对照试验数据。
主要发现
- COVID-19与高发生率血栓并发症相关,涉及病毒与内皮细胞、炎症反应及凝血系统的复杂相互作用。
- 非危重住院患者中,治疗剂量低分子肝素可能改善临床结局。
- 危重患者中,治疗剂量低分子肝素不改善结局。
关键数值与推荐
- 门诊及出院后患者不常规推荐药物性血栓预防。
- 危重患者推荐预防剂量抗凝进行血栓预防。
临床怎么用
- 根据患者疾病阶段(门诊、非危重住院、危重、出院后)选择抗血栓策略。
- 非危重住院患者可考虑治疗剂量低分子肝素以改善临床结局。
- 危重患者使用预防剂量抗凝,而非治疗剂量。
局限性
- 高质量直接证据不足导致部分推荐为弱推荐。
- 需等待正在进行的大量抗血栓研究数据以指导不同疾病阶段的临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COVID-19 is associated with a high incidence of thrombotic complications, which can be explained by the complex and unique interplay between coronaviruses and endothelial cells, the local and systemic inflammatory response, and the coagulation system. Empirically, an intensified dose of thrombosis prophylaxis is being used in patients admitted to hospital with COVID-19 and several guidelines on this topic have been published, although the insufficiency of high quality and direct evidence has led to weak recommendations. In this Viewpoint we summarise the pathophysiology of COVID-19 coagulopathy in the context of patients who are ambulant, admitted to hospital, and critically ill or non-critically ill, and those post-discharge from hospital. We also review data from randomised controlled trials in the past year of antithrombotic therapy in patients who are critically ill. These data provide the first high-quality evidence on optimal use of antithrombotic therapy in patients with COVID-19. Pharmacological thromboprophylaxis is not routinely recommended for patients who are ambulant and post-discharge. A first ever trial in non-critically ill patients who were admitted to hospital has shown that a therapeutic dose of low-molecular-weight heparin might improve clinical outcomes in this population. In critically ill patients, this same treatment does not improve outcomes and prophylactic dose anticoagulant thromboprophylaxis is recommended. In the upcoming months we expect numerous data from the ongoing antithrombotic COVID-19 studies to guide clinicians at different stages of the disease.
引用
- Leentjens J, van Haaps TF, Wessels PF, et al. COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year. Lancet Haematol. 2021. PMID: 33930350. doi:10.1016/S2352-3026(21)00105-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。